OBJECTIVE: Stereotactic body radiation therapy (SBRT) has been successfully used to treat oligometastases of several primary tumors, but few experiences have been described in patients with gynecological oligometastatic cancer, particularly in ovarian neoplasm. The aim of this study was to evaluate the role of this new radiotherapy modality in a series of oligometastatic ovarian cancer patients. MATERIALS AND METHODS: Clinical records of patients affected by oligometastatic ovarian carcinoma treated with SBRT were reviewed. RESULTS: Twenty-six patients with 44 metastatic lesions (lymph nodes, 63.6%; liver, 31.8%; and lung, 4.5%) treated with SBRT between January 2011 and May 2017 were analyzed. After a median follow-up period of 28.5 months (range, 6-86 months), 17 patients (65.4%) were still alive at time of analysis: 6 are without evidence of disease, 11 experienced a disease progression. Eight patients died of disease, 1 died because of an heart attack while being disease free. The median local control (LC) was not reached. One-, 2-, and 5-year LCs were 92.9%. Median progression-free survival was 19 months, with 1-year progression-free survival of 69.3% and 38% at 2 years, 19% at 5 years. Median overall survival was 64.5 months, with all patients alive after 1 year, 92.7% at 2 years, and 61.7% at 5 years. Five (11.3%) cases experienced G2 toxicity; most common adverse effect was nausea and vomiting (3 cases [6.8%]) followed by abdominal pain (2 cases [4.5%]). None of the patients had grade 3 or grade 4 acute or late toxicity. CONCLUSIONS: In conclusion, SBRT is a feasible and safe approach for selected cases of oligometastatic ovarian cancer, with satisfactory results in terms of LC and disease free survival.
OBJECTIVE: Stereotactic body radiation therapy (SBRT) has been successfully used to treat oligometastases of several primary tumors, but few experiences have been described in patients with gynecological oligometastatic cancer, particularly in ovarian neoplasm. The aim of this study was to evaluate the role of this new radiotherapy modality in a series of oligometastatic ovarian cancerpatients. MATERIALS AND METHODS: Clinical records of patients affected by oligometastatic ovarian carcinoma treated with SBRT were reviewed. RESULTS: Twenty-six patients with 44 metastatic lesions (lymph nodes, 63.6%; liver, 31.8%; and lung, 4.5%) treated with SBRT between January 2011 and May 2017 were analyzed. After a median follow-up period of 28.5 months (range, 6-86 months), 17 patients (65.4%) were still alive at time of analysis: 6 are without evidence of disease, 11 experienced a disease progression. Eight patients died of disease, 1 died because of an heart attack while being disease free. The median local control (LC) was not reached. One-, 2-, and 5-year LCs were 92.9%. Median progression-free survival was 19 months, with 1-year progression-free survival of 69.3% and 38% at 2 years, 19% at 5 years. Median overall survival was 64.5 months, with all patients alive after 1 year, 92.7% at 2 years, and 61.7% at 5 years. Five (11.3%) cases experienced G2 toxicity; most common adverse effect was nausea and vomiting (3 cases [6.8%]) followed by abdominal pain (2 cases [4.5%]). None of the patients had grade 3 or grade 4 acute or late toxicity. CONCLUSIONS: In conclusion, SBRT is a feasible and safe approach for selected cases of oligometastatic ovarian cancer, with satisfactory results in terms of LC and disease free survival.
Authors: Gabriella Macchia; Roberta Lazzari; Nicoletta Colombo; Concetta Laliscia; Giovanni Capelli; Giuseppe Roberto D'Agostino; Francesco Deodato; Ernesto Maranzano; Edy Ippolito; Sara Ronchi; Fabiola Paiar; Marta Scorsetti; Savino Cilla; Rossana Ingargiola; Alessandra Huscher; Anna Maria Cerrotta; Andrei Fodor; Lisa Vicenzi; Donatella Russo; Simona Borghesi; Elisabetta Perrucci; Sandro Pignata; Cynthia Aristei; Alessio Giuseppe Morganti; Giovanni Scambia; Vincenzo Valentini; Barbara Alicja Jereczek-Fossa; Gabriella Ferrandina Journal: Oncologist Date: 2019-10-10
Authors: Timothy D Smile; Chandana A Reddy; George Qiao-Guan; W Ian Winter; Kevin L Stephans; Neil M Woody; Ehsan H Balagamwala; Sudha R Amarnath; Anthony Magnelli; Mariam M AlHilli; Chad M Michener; Haider Mahdi; Robert L DeBernardo; Peter G Rose; Sheen S Cherian Journal: J Radiosurg SBRT Date: 2021
Authors: Roman O Kowalchuk; Michael R Waters; K Martin Richardson; Kelly Spencer; James M Larner; William P Irvin; Charles R Kersh Journal: Radiat Oncol Date: 2020-05-13 Impact factor: 3.481
Authors: Rosa Maria Leon-Salas Ordoñez; Beatriz E Amendola; Paul F Martinez; Aizik Wolf; Sammie R Coy; Marco Amendola Journal: Rep Pract Oncol Radiother Date: 2019-10-30
Authors: Roman O Kowalchuk; Michael R Waters; Sunil W Dutta; Marie L Mack; K Martin Richardson; Kelly Spencer; Kara D Romano; James M Larner; Jason P Sheehan; C Ronald Kersh Journal: Adv Radiat Oncol Date: 2020-11-10